share_log

10-Q: Q3 2024 Earnings Report

10-Q: Q3 2024 Earnings Report

10-Q:2024財年三季報
美股SEC公告 ·  2024/11/12 21:08

牛牛AI助理已提取核心訊息

GeoVax Labs reported Q3 2024 financial results, with revenue of $2.8 million primarily from the BARDA contract for COVID-19 vaccine development, compared to no revenue in Q3 2023. Net loss narrowed to $5.8 million from $8.4 million year-over-year. Research and development expenses increased 6.5% to $7.4 million, while general and administrative costs decreased 24.9% to $1.2 million.The company's cash position strengthened to $8.6 million as of September 30, 2024, up from $6.5 million at year-end 2023, bolstered by approximately $19.1 million in net proceeds from equity offerings and warrant exercises. The BARDA contract, valued at up to $45 million, will fund manufacturing and support for a 10,000-participant Phase 2b trial of GEO-CM04S1 COVID-19 vaccine.Management believes current cash reserves will fund operations into Q1 2025. Key clinical programs include GEO-CM04S1 in multiple Phase 2 trials for COVID-19 prevention and Gedeptin for advanced head and neck cancer, which is advancing toward an expanded Phase 2 trial planned for first half of 2025.
GeoVax Labs reported Q3 2024 financial results, with revenue of $2.8 million primarily from the BARDA contract for COVID-19 vaccine development, compared to no revenue in Q3 2023. Net loss narrowed to $5.8 million from $8.4 million year-over-year. Research and development expenses increased 6.5% to $7.4 million, while general and administrative costs decreased 24.9% to $1.2 million.The company's cash position strengthened to $8.6 million as of September 30, 2024, up from $6.5 million at year-end 2023, bolstered by approximately $19.1 million in net proceeds from equity offerings and warrant exercises. The BARDA contract, valued at up to $45 million, will fund manufacturing and support for a 10,000-participant Phase 2b trial of GEO-CM04S1 COVID-19 vaccine.Management believes current cash reserves will fund operations into Q1 2025. Key clinical programs include GEO-CM04S1 in multiple Phase 2 trials for COVID-19 prevention and Gedeptin for advanced head and neck cancer, which is advancing toward an expanded Phase 2 trial planned for first half of 2025.
GeoVax Labs公佈了2024年第三季度的財務結果,營業收入爲280萬美元,主要來自BARDA合同下的COVID-19生物-疫苗開發,而2023年第三季度沒有收入。淨虧損從去年同期的840萬美元縮小至580萬美元。研究與開發費用增加了6.5%,達到740萬美元,而一般及行政支出減少了24.9%,降至120萬美元。截至2024年9月30日,公司現金狀況增強,達到860萬美元,比2023年年末的650萬美元有所增加,這得益於約1910萬美元的股票發行和認股權證行使的淨收入。BARDA合同的價值最高可達4500萬美元,將用於資助製造業及支持一項有10000名參與者的GEO-CM04S1 COV...展開全部
GeoVax Labs公佈了2024年第三季度的財務結果,營業收入爲280萬美元,主要來自BARDA合同下的COVID-19生物-疫苗開發,而2023年第三季度沒有收入。淨虧損從去年同期的840萬美元縮小至580萬美元。研究與開發費用增加了6.5%,達到740萬美元,而一般及行政支出減少了24.9%,降至120萬美元。截至2024年9月30日,公司現金狀況增強,達到860萬美元,比2023年年末的650萬美元有所增加,這得益於約1910萬美元的股票發行和認股權證行使的淨收入。BARDA合同的價值最高可達4500萬美元,將用於資助製造業及支持一項有10000名參與者的GEO-CM04S1 COVID-19生物-疫苗的20億試驗。管理層相信,當前的現金儲備將能夠支持運營直到2025年第一季度。關鍵臨牀項目包括GEO-CM04S1在多個階段2試驗中進行COVID-19預防,以及Gedeptin用於晚期頭頸癌,後者正向計劃於2025年上半年進行的擴展階段2試驗推進。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 695

熱點推薦

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。